Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) & SCYNEXIS (NASDAQ:SCYX)

Madrigal Pharmaceuticals (NASDAQ:MDGL) and SCYNEXIS (NASDAQ:SCYX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Volatility & Risk

Madrigal Pharmaceuticals has a beta of -0.46, meaning that its stock price is 146% less volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Madrigal Pharmaceuticals and SCYNEXIS, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Madrigal Pharmaceuticals	1	2	10	0	2.69
SCYNEXIS	0	0	1	0	3.00

Madrigal Pharmaceuticals presently has a consensus target price of $347.33, indicating a potential upside of 9.04%. Given Madrigal Pharmaceuticals’ higher possible upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than SCYNEXIS.

Valuation and Earnings

This table compares Madrigal Pharmaceuticals and SCYNEXIS”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Madrigal Pharmaceuticals	N/A	N/A	-$373.63 million	($25.08)	-12.70
SCYNEXIS	$140.14 million	0.36	$67.04 million	($0.74)	-1.78

SCYNEXIS has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 22.8% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 2.9% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Madrigal Pharmaceuticals and SCYNEXIS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Madrigal Pharmaceuticals	N/A	-71.78%	-53.25%
SCYNEXIS	-425.41%	-66.21%	-38.84%

Summary

SCYNEXIS beats Madrigal Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

About SCYNEXIS

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.